Buy Gland Pharma Ltd for Target Rs.3,667 by Axis Direct
Investment Rationale
A. Capacity Expansion & Rising Manufacturing Utilisation
Gland Pharma is accelerating capacity expansion to address strong demand and emerging capacity constraints across key injectable formats. Existing capacity utilisation has reached approximately 92%, with management expecting it to exceed 100% next year in certain product lines. The company has announced an additional Rs 1,000 Cr brownfield investment at Pashamylaram, involving three new manufacturing lines, while a longer-term greenfield project at Visakhapatnam will support future growth
B. Improving Profitability & Margin Expansion
The company is witnessing strong operating leverage, supported by higher volumes, favourable product mix and improved business performance. Q2FY27 revenue grew 23% YoY to Rs 1,834 Cr, while EBITDA increased 53% to Rs 480 Cr, expanding margins to 26% from 21% in Q2FY26. Adjusted EBITDA margin improved to 27%, while PAT rose 58% to Rs 291 Cr. Continued scale-up in CDMO operations, better capacity utilisation and operational efficiencies are expected to support sustained profitability improvement.
C. Comprehensive Product Portfolio, CDMO Growth & China Partnerships
Gland Pharma's portfolio spans complex injectables, oncology, ophthalmology and speciality formulations, with CDMO contributing 45% of Q2FY27 revenue, growing 31% YoY. The company is expanding into differentiated segments such as microspheres, peptides and long-acting injectables. Its China strategy, including two in-licensing arrangements for long-acting injectables, offers access to innovative molecules and advanced technologies for manufacturing in India. The recent approval of Eli Lilly's oral GLP-1 drug in China further highlights the country's growing pharmaceutical innovation potential.
Outlook & Valuation
Gland Pharma's growth outlook is supported by expanding CDMO partnerships, rising demand for complex injectables and a strong product pipeline. Management targets ~15% FY27 revenue growth (constant currency), while capacity expansion across existing facilities and the proposed Vizag greenfield project are expected to drive higher volumes, operating leverage and sustained margin improvement.
Analyst Insights
We recommend a BUY on the stock with a TP of Rs 3,667/share implying an upside of 10% from the CMP.
For More Axis Securities Disclaimer https://simplehai.axisdirect.in/disclaimer-home
SEBI Registration number is INZ000161633
